Source: KREM 2 News - CBS
Author: Rose Beltz
Published: August 21, 2018
Alan Tan, MD, Clinical Research Medical Director & Medical Oncologist and Hematologist, Cancer Treatment Centers of America® (CTCA), Phoenix discusses how talimogene laherparepvec (T-VEC) uses a genetically modified herpes virus to treat melanoma lesions.
The virus is injected directly into tumors, and triggers a response in the immune system which enables it to detect and attack cancer cells throughout the body.